
    
      The study will include patients with a variety of solid tumors (i.e. esophageal, colon,
      pancreatic, bronchial, gastric, hepatocellular, gall bladder, prostate and gynaecological
      carcinomas.)

      The clinical benefit response - CBR, is an end point that provides a clinical measure for
      symptom improvement in patients. The key evaluation parameters for CBR will be assessment of
      pain, the ability to perform daily activities and weight change.
    
  